Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) With or Without Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies

NCT03435640 is registered in ClinicalTrials.gov with Nektar Therapeutics as lead sponsor.

NCT NCT03435640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03435640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) With or Without Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies
Lead sponsor
Nektar Therapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
March 15, 2018
Completion date
May 9, 2022
Enrollment
64 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, head and neck squamous cell carcinoma, melanoma, merkel cell carcinoma, renal cell carcinoma, sarcoma, triple negative breast cancer